© Lynn Herbert Ratner MD

Ovarian and Uterine Cancer Basics disclaimer

Staff One

Valuable Ovarian and Uterine Cancer Resources

The National Cancer Institute information for patients about
ovarian cancer

Staff One

The National Library of Medicine
information for patients about
uterine cancer

Staff One

The American Cancer Society information for patients about
uterine cancer (pdf file)

Lynn H Ratner MD
Dialecti Voudouris MD
Paul A C Greenberg MD

112 East 83rd Street
New York City NY 10028
tel: 1-212-396-0400 fax: 1-212-396-9800

Click for appointment and contact information

ManhattanCancerSpecialists.com

Doctors Ratner, Voudouris and Greenberg

Staff One

The National Cancer Institute information for patients about
uterine cancer

Staff One

The National Library of Medicine
-Plain teaching module for patients about ovarian cancer

Staff One

The American Cancer Society information for patients about
ovarian cancer

Para Español clic acqui
Para Español clic acqui
Para Español clic acqui
Para Español clic acqui
Office entrance Ratner, Voudouris, Greenberg

Ovarian cancer poses special problems and challenges for the patient and her physician. The doctors in our practice have been involved to varying degrees in ovarian cancer research dating back over 30 years. We approach each patient with an outlook towards cure.

In the case of the ovary, when cells in this organ begin to grow out of control, the potential for metastasis or spread exists. It is important for the team at Manhattan Cancer Specialists to combine with a gynecologic oncologist to manage this disease. In addition, we will seek the contribution of radiologists and the patient's own gynecologist.

The general outlook for patients with ovarian cancer is improving greatly in recent years. When one is diagnosed in the earlier stages the five-year survival rate is over 90%. However, only a small fraction of cases are found at the early stage because of the nonspecific symptoms and the lack of an early diagnostic test.

Cyto-reductive surgery, meaning the removal of as much tumor as possible at the initial surgery, is quite important in making sure that the patient has a better outlook. Thus, diagnostic tests such as the pelvic examination, transvaginal sonography utilizing ultrasound, and the CA-125 blood test are quite important even though this blood test is not always accurate, and there are non-cancerous diseases which may elevate this test.

The treatment following the cyto-reductive surgery usually consists of chemotherapy. Dr. Ratner of this group participated in the early use of cis-platinum chemotherapy after its introduction in the early 1970s. Platinum chemotherapy derivatives still are the mainstay of treatment of primary ovarian cancer.

Targeted therapies such as the drug Avastin (R) show much promise; and wherever needed, we will make every effort to utilize that technique of targeted therapy in the management of our patients. If you would like to read more about ovarian or uterine cancer, we have provided several links at the right to authoritative sources about these diseases, their treatments and support. We want you to know that the doctors in this office and our excellent Oncology staff will be available to you at all times, supportive in all aspects of your care and we encourage your questions and input.